U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. Drug Safety and Availability
  4. FDA warns cancer patients not to use PNC-27 products for treatment
  1. Drug Safety and Availability

FDA warns cancer patients not to use PNC-27 products for treatment

[Update: 3/27/2017] An FDA laboratory tested another sample of PNC-27 solution for inhalation and found the bacteria Ralstonia insidiosa.

[1/10/2017] The Food and Drug Administration is warning consumers not to purchase or use PNC-27, a product promoted and sold through http://PNC27.comdisclaimer icon, as a treatment or cure for cancer. An FDA laboratory discovered the bacteria Variovorax paradoxus in a PNC-27 solution sample for inhalation.

Consumers who use a contaminated product are at risk for serious, potentially life-threatening infections. Consumers at higher risk include vulnerable populations, such as young children, elderly people, pregnant women, and individuals with weakened immune systems.

PNC-27 may be available in various dosage forms, such as a nebulized solution, intravenous solution, vaginal suppository, or rectal suppository. FDA has not evaluated or approved PNC-27 as safe and effective to treat any disease, including any form of cancer.

FDA recommends patients with cancer discuss treatment options with a licensed health care professional. Patients who have used any PNC-27 product and have concerns should contact their health care provider as soon as possible.

The agency has not received reports of illnesses or serious adverse events related to PNC-27. FDA encourages health care professionals and consumers to report any adverse events possibly related to the use of a PNC-27 product to FDA’s MedWatch Adverse Event Reporting Program:

 

Back to Top